H. Rask-Andersen, Liu Wei, A. Kinnefors, K. Pfaller, R. Glueckert, A. Schrott-Fischer, M. Boström
More than 600 million people suffer from neurosensory diseases, with hearing loss being one of the dominant causes of all ages. Deafness affects 2-3 children in 1000 born, over 10% of adults and 30 ...
{"title":"Studies of the Human Cochlea with Aspects on Future Hearing Rehabilitation","authors":"H. Rask-Andersen, Liu Wei, A. Kinnefors, K. Pfaller, R. Glueckert, A. Schrott-Fischer, M. Boström","doi":"10.11289/OTOLJPN.20.119","DOIUrl":"https://doi.org/10.11289/OTOLJPN.20.119","url":null,"abstract":"More than 600 million people suffer from neurosensory diseases, with hearing loss being one of the dominant causes of all ages. Deafness affects 2-3 children in 1000 born, over 10% of adults and 30 ...","PeriodicalId":19601,"journal":{"name":"Otology Japan","volume":"9 1","pages":"119-129"},"PeriodicalIF":0.0,"publicationDate":"2010-05-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74501242","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Colletti, R. Shannon, M. Mandalà, M. Carner, S. Veronese, L. Colletti
INTRODUCTION Auditory restoration with implant technology has been a great success story in otology and the ultimate limits of the technology are still not known. Today there are a wide variety of approaches and auditory prostheses for restoration of hearing, each with a precise indication for specific degrees and sites of hearing loss (Figure 1). Modern auditory prostheses range from implants that impart mechanical energy to the cochlea (middle ear implants, MEIs) via the ossicular chain or bypass a damaged ossicular chain and vibrate the round window directly (round window implants, RWI). Cochlear implants (CIs) bypass damaged inner ear cells and electrically stimulate the auditory nerve within the cochlea. The auditory brainstem implant (ABI) bypasses a damaged cochlea and auditory nerve auditory and directly stimulate the brainstem nuclei. The inferior colliculus implant (ICI) or auditory midbrain implant (AMI) bypass damaged brainstem nuclei to stimulate the inferior colliculus in the midbrain. With the refinements in implant technology, patient selection criteria for the various implant devices need to be periodically reconsidered with a view to obtaining increasingly high levels of speech recognition for the different etiologies. In general it is thought that the more peripheral the implant, the better the chance of success. Indeed the more peripheral implants (RW, MEIs, CIs and ABIs in non-NF2 patients) have been 第19回日本耳科学会特別講演3
{"title":"Recent Developments in Bionic Hearing Restoration from the Round Window to the Inferior Colliculus","authors":"Colletti, R. Shannon, M. Mandalà, M. Carner, S. Veronese, L. Colletti","doi":"10.11289/OTOLJPN.19.677","DOIUrl":"https://doi.org/10.11289/OTOLJPN.19.677","url":null,"abstract":"INTRODUCTION Auditory restoration with implant technology has been a great success story in otology and the ultimate limits of the technology are still not known. Today there are a wide variety of approaches and auditory prostheses for restoration of hearing, each with a precise indication for specific degrees and sites of hearing loss (Figure 1). Modern auditory prostheses range from implants that impart mechanical energy to the cochlea (middle ear implants, MEIs) via the ossicular chain or bypass a damaged ossicular chain and vibrate the round window directly (round window implants, RWI). Cochlear implants (CIs) bypass damaged inner ear cells and electrically stimulate the auditory nerve within the cochlea. The auditory brainstem implant (ABI) bypasses a damaged cochlea and auditory nerve auditory and directly stimulate the brainstem nuclei. The inferior colliculus implant (ICI) or auditory midbrain implant (AMI) bypass damaged brainstem nuclei to stimulate the inferior colliculus in the midbrain. With the refinements in implant technology, patient selection criteria for the various implant devices need to be periodically reconsidered with a view to obtaining increasingly high levels of speech recognition for the different etiologies. In general it is thought that the more peripheral the implant, the better the chance of success. Indeed the more peripheral implants (RW, MEIs, CIs and ABIs in non-NF2 patients) have been 第19回日本耳科学会特別講演3","PeriodicalId":19601,"journal":{"name":"Otology Japan","volume":"143 1","pages":"677-685"},"PeriodicalIF":0.0,"publicationDate":"2009-12-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90540398","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
H. Rask-Andersen, Wei Liu, M. Boström, F. Linthicum
Cochlear Implantation (CI) remains as one of the greatest medical achievements in modern medicine. New and innovative strategies continue to be developed to optimize and improve the functional results of CI surgery. Preservation of residual hearing through a-traumatic surgical techniques and electrode arrays may alter indications. Conditions with profound SNHL with preserved low tone hearing may have several causes and pathology may vary accordingly. In patients with progressive adult-onset SNHL neurons may be conserved even after long duration of deafness. IHCs and OHCs, supporting cells, ganglion cells and dendrites may be preserved in the apical region while in the lower turn despite atrophic organ of Corti and loss of lamina fibers ganglion cells can be present even after 28 years duration of deafness. These spiral ganglion cells may be excellent targets for electric stimulation using EAS technique that combines electric and acoustic stimulation in the same ear and utilizes both low frequency acoustic hearing and electric stimulation of preserved neurons. At the moment we are trying to elucidate the mechanism responsible for this preservation in humans and to use this knowledge for future therapy. Nano-technology may offer new possibilities for focused release of drugs and possibly genes to the inner ear. European project“NanoEar”is a concerted action to develop 3rd generation of nanoparticles (NP) for treatment of inner ear deafness. One goal is to target drugs and genes to specific inner ear cells through so-called multifunctional NP which are degradable, non-toxic, traceable and can be released in a controlled and biocompatible way. The small size of the NP may give new properties for technical advancement but risks must also be thoroughly evaluated. Uppsala is a Swedish partner to evaluate NP uptake in vitro in both human and animal spiral ganglion neurons. In my presentation I will show the system of culture spiral ganglion cells and demonstrate their locomotive behaviour and NP intracellular uptake using time lapse video recording and combined immunofluorescence and confocal microscopy.
{"title":"Hearing Preservation and Nanotechnology-based Targeted Drug Delivery Future in Cochlear Implantation?","authors":"H. Rask-Andersen, Wei Liu, M. Boström, F. Linthicum","doi":"10.11289/OTOLJPN.19.687","DOIUrl":"https://doi.org/10.11289/OTOLJPN.19.687","url":null,"abstract":"Cochlear Implantation (CI) remains as one of the greatest medical achievements in modern medicine. New and innovative strategies continue to be developed to optimize and improve the functional results of CI surgery. Preservation of residual hearing through a-traumatic surgical techniques and electrode arrays may alter indications. Conditions with profound SNHL with preserved low tone hearing may have several causes and pathology may vary accordingly. In patients with progressive adult-onset SNHL neurons may be conserved even after long duration of deafness. IHCs and OHCs, supporting cells, ganglion cells and dendrites may be preserved in the apical region while in the lower turn despite atrophic organ of Corti and loss of lamina fibers ganglion cells can be present even after 28 years duration of deafness. These spiral ganglion cells may be excellent targets for electric stimulation using EAS technique that combines electric and acoustic stimulation in the same ear and utilizes both low frequency acoustic hearing and electric stimulation of preserved neurons. At the moment we are trying to elucidate the mechanism responsible for this preservation in humans and to use this knowledge for future therapy. Nano-technology may offer new possibilities for focused release of drugs and possibly genes to the inner ear. European project“NanoEar”is a concerted action to develop 3rd generation of nanoparticles (NP) for treatment of inner ear deafness. One goal is to target drugs and genes to specific inner ear cells through so-called multifunctional NP which are degradable, non-toxic, traceable and can be released in a controlled and biocompatible way. The small size of the NP may give new properties for technical advancement but risks must also be thoroughly evaluated. Uppsala is a Swedish partner to evaluate NP uptake in vitro in both human and animal spiral ganglion neurons. In my presentation I will show the system of culture spiral ganglion cells and demonstrate their locomotive behaviour and NP intracellular uptake using time lapse video recording and combined immunofluorescence and confocal microscopy.","PeriodicalId":19601,"journal":{"name":"Otology Japan","volume":"42 1","pages":"687-697"},"PeriodicalIF":0.0,"publicationDate":"2009-12-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80664669","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：